Skip to content
Open access

Effectiveness of timely hepatitis B birth dose vaccination to prevent mother-to-child transmission in Ethiopia.

Sep 2026 · Clinical Infectious Diseases · 0 citations
Medicine

TL;DR

Timely HepB-BD is highly effective in reducing HBV MTCT and should be prioritised for scale-up in Africa.

Abstract

Background

Mother-to-child transmission (MTCT) is an important route of new hepatitis B virus (HBV) infections. In Africa, limited and conflicting data on the effectiveness of hepatitis B birth dose vaccination (HepB-BD) have contributed to fragmented adoption and sub-optimal implementation. We aimed to assess the effectiveness of timely HepB-BD in preventing HBV MTCT in Ethiopia.

Methods

We conducted a multi-centre cross-sectional observational study in Ethiopia from May 2022 to June 2024. We identified mothers who had tested positive for hepatitis B surface antigen (HBsAg) during pregnancy and assessed mother-infant pairs at 6-12 months post-partum for HBV MTCT. We stratified effectiveness of HepB-BD by maternal risk profile (HBV DNA level, hepatitis B e-antigen (HBeAg) status).

Results

The analysis included 387 children born to HBV-positive, HIV-negative mothers who had completed routine HBV vaccination (HepB3). The median age of infant testing was 10 months (IQR 7.0-11). Overall MTCT risk was 5.2% (95% CI 3.4,7.8). MTCT was significantly lower among infants receiving HepB-BD alone (0/39, 0% [95% CI 0-9.0]) compared to those without immunoprophylaxis at birth (20/131, 15.3% [95% CI 10.1-22.4]) (p = 0.009). No transmission occurred with HepB-BD plus HBIg (0/217, 0% [95% CI 0-1.7]). Maternal viral load >200,000 IU/ml (AOR 16.6, 95% CI 4.82,57.19) and HBeAg positivity (AOR 4.21, 95% CI 1.08,16.44) were associated with increased MTCT risk amongst infants without immunoprophylaxis at birth.

Conclusions

In Ethiopia, the current vaccination series starting at 6 weeks is insufficient to prevent HBV MTCT. Timely HepB-BD is highly effective in reducing HBV MTCT and should be prioritised for scale-up in Africa.

Read PDF

Similar papers

Open access Oct 2026

Hepatitis B elimination in Africa by 2030 requires urgent scale up of birth dose vaccination, maternal antiviral prophylaxis and political action

Hepatitis B elimination in Africa is unlikely to be achieved by 2030 unless prevention and care systems are urgently strengthened. Despite progress in infant vaccination, the World Health Organization (WHO) African Region continues to have very low timely hepatitis B birth-dose coverage and major gaps in diagnosis and...

Abdishakur Ahmed Mahad, Abdisamad Abdihakim Aadam, Zakia Abdalla Rashiid et al. · 0 citations
Review

Social determinants of timely administration of Hepatitis B vaccination among children in Vietnam, 2020-2021

Vietnam has a high prevalence of Hepatitis B (HBV) and liver cancer. Although Hepatitis B vaccination has been implemented since 2003 in the Expanded Programme on Immunization, coverage remains low. This study aims to examine the timeliness rate and the social determinants of timely administration of HBV vaccination am...

Phuong Phuong Pham · 0 citations
Review Open access Sep 2026

Contact without protection: high antenatal attendance, minimal hepatitis B testing in Nigerias mother-to-child prevention cascade -- how far from elimination?

Hepatitis B is a leading preventable cause of liver cancer, and in high-burden settings most chronic infection is acquired around birth. Nigeria carries Africas largest hepatitis B burden. Preventing mother-to-child transmission requires a chain of antenatal steps: testing pregnant women, acting on the result, and vacc...

S. Abanni, B. M. Ekure, J. Omotosho · 0 citations
Open access Oct 2026

Hepatitis B Immunoprophylaxis rarely prevents molecularly evident subclinical HBV infection in children born to HBsAg-positive mothers

Hepatitis B virus (HBV) remains one of the most life-threatening human pathogens causing chronic hepatitis B and hepatocellular carcinoma in millions of people globally. Protective vaccines are available for decades, but their implementation is not yet universal. Mother-to-child transmission remains the prevailing rout...

Liang Xu, Qing-Hai Dai, Hui-Li Yang et al. · 0 citations
Review Open access Nov 2026

Hepatitis B seroprevalence among children aged 0.6-14 years in Jiangsu, China, in 2023-2025.

China has implemented universal hepatitis B vaccination in all neonates since 2002 and has enhanced prophylaxis against mother-to-child transmission of hepatitis B virus (HBV) by providing charge-free hepatitis B immunoglobulin in infants of HBV-infected mothers since 2011 and by recommending routine antiviral prophyla...

N. Lin, Chen-Yu Xu, Chang Liu et al. · 0 citations
Open access Nov 2026

Immune Response to Hepatitis B Vaccination According to National EPI Schedule among Children Below 2 Years

Background: Hepatitis B virus infection is a public health burden globally. We incorporate Hep-B vaccine in our EPI schedule. There is no comprehensive data regarding the immune response of the HBV vaccine at one year in our country. The study was done to assess the immune response among HBV vaccinated children at this...

Kamrun Nahar, Aparup Das, Shanjana Islam et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.